We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info.

Confirm

Improving the lives of patients is our mission. We are an ambitious and dynamic business with a healthy innovation-driven pipeline that enables us to build on our core expertise in pain. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. This commitment to innovation and thought-leadership means that next generation scientific talent is drawn to us.

Grünenthal. Change is possible.

locations
32

We are present in 32 countries with affiliates in Europe, Latin America and the US.

market presence
100

Our products are sold in more than 100 countries.

employees
5,200

5,200 employees work for our group worldwide.

Success can only be achieved through close collaborations with those who share the same vision.


Please read more about our projects supported by resources of the European Regional Development Fund

... Read More

What we do

As a fully integrated research & development company we bring innovative pain treatments and state-of-the-art technologies to patients.

... Learn more about Grünenthal

Pioneering thinkers

Our passion is innovation. We are driven to seek new solutions for patients with severe diseases and high unmet medical needs – and make these solutions accessible to patients.
... Find out more

Careers

Ready to create a brighter future for our patients?
With us, let your passion and ideas flow and drive innovation to improve our patients’ lives.

... Work with Grünenthal

Featured news & articles

Neuroweg

The future of pain medicines

The Leitmarktwettbewerb LifeSciences.NRW project “NeuRoWeg”: How will we test the efficacy of pain medicines in the future? ? An important question that we intend to answer.

Author: Dr. Gregor Bahrenberg

Vulvodynia

Leading the way

Courageous women are speaking out about their experiences of Vulvodynia: And our experts are leading the way toward an innovative medicine for this under-recognised and often stigmatized condition.

Author: Dr. Philipp Wabnitz

Neridronate

Giving CRPS patients hope

Neridronate is giving hope to those affected by CRPS – one of the most painful conditions a patient can experience.

Author: Dr. Katrin Fleischer

Flix® & VIVO

Giving peace of mind

Our innovative surgical glues may offer surgeons an innovative alternative to existing surgical wound closure and management techniques for increased wound healing outcome.

Author: Dr. Nadja Oellers

6/21/2018

Aachen, Dortmund and Göttingen, Germany, June 21, 2018 – Grünenthal, Lead Discovery Center GmbH (LDC), Max-Planck Innovation and Max Planck Institute of Experimental Medicine (MPI-EM) have entered into a research collaboration to develop novel therapies for patients suffering from Charcot-Marie-Tooth 1A (CMT1A), an inherited neurological disorder. The collaboration combines the disease proficiency of MPI-EM, the drug discovery expertise of LDC and Grünenthal’s competency in drug discovery and development as well as pain management. The project’s scientific foundation was laid at MPI-EM by Michael Sereda, Klaus-Armin Nave and Moritz Rossner.

6/18/2018

Diegem/Aachen, 18 June 2018. The number of patients suffering from pain is immense. In a recent ‘European Pain Management’ publication (Oxford University Press, 2018), Christopher Eccleston, Bart Morlion and Christopher Wells shared that of approximately 740 million people in the 37 member states of the European Pain Federation EFIC®, approximately 150 million people suffer from chronic pain. This number is equivalent to the populations of both France and Germany combined. The data clearly highlight that pain research is more important than ever. Through the support of the E-G-G Award, young scientists are encouraged to further develop and implement their research ideas.

6/12/2018

Aachen, Germany, 15 June 2018 – Grünenthal has qualified as one of the 25 Best Multinational Workplaces in Europe this year. After 2012 and 2013, this is the third time that Grünenthal, a science-based pharmaceutical company headquartered in Germany, is being awarded in this category. National successes in Italy, Portugal and Spain were the reasons for the decision by the Great Place to Work® (GPtW®) Institute.

6/12/2018

Aachen, Germany, June 12, 2018 – Grünenthal announced today that first patients have been enrolled in two trials of the company’s pivotal phase III program investigating neridronate for the treatment of Complex Regional Pain Syndrome (CRPS). These two trials, KF7013-02 and KF7013-04, are investigating the efficacy and safety of neridronate in 360 patients with CRPS. Neridronate, a bisphosphonate, is an innovative investigational medicine discovered and developed by Abiogen Pharma and now being further developed by Grünenthal for the US territory.

6/5/2018

June 05, 2018 – To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched the research project “IMI-PainCare – Improving the care of patients suffering from acute or chronic pain” on April 01, 2018.